Workflow
天坛生物(600161) - 2016 Q1 - 季度业绩预告
BTBPBTBP(SH:600161)2016-04-15 16:00

Financial Performance - The company expects a net loss of approximately -700,000 yuan for Q1 2016, compared to a net profit of 12,098,400 yuan in the same period last year[2][3] - Earnings per share for the previous year was 0.02 yuan[3] Sales and Revenue - The decline in sales revenue for vaccine products is attributed to a decrease in sales of the measles, mumps, and rubella series products and a drop in sales of the varicella vaccine from a subsidiary[4] Operational Challenges - Increased fixed costs due to the large scale of the new factory in Yizhuang, leading to higher depreciation and energy consumption[4] - The relocation of the hepatitis B vaccine workshop to the new factory resulted in increased downtime costs[4] - The company is still in the process of reaching reasonable production capacity at the new factory, making it difficult to achieve economies of scale in the short term[4] Data and Reporting - The data provided is preliminary and subject to change, with the final financial figures to be disclosed in the official Q1 2016 report[5]